C
Chimagen Biosciences
Developing innovative medicine to address the unmet medical needs in the area of oncology
About Chimagen Biosciences
Chimagen Biosciences is a biotechnology firm focused on the discovery and development of therapeutic monoclonal antibodies. The company directs its research and clinical studies towards treatments for cancer and autoimmune diseases.
A significant development for the company is its clinical-stage therapy, CMG1A46, which is designed to target B cell-driven autoimmune diseases. This asset has attracted major attention from the pharmaceutical industry, culminating in an acquisition agreement with GlaxoSmithKline (GSK). Under the terms of the deal, GSK will acquire CMG1A46 for an upfront payment of $300 million, with the total value of the transaction potentially reaching $850 million. This event highlights the company's business model of developing high-value therapeutic candidates for acquisition by larger pharmaceutical corporations, thereby generating revenue through milestone payments and upfront fees.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Oct 2024 | $100M | $400M | GSK | ↗ |
Growth signals
Latest recorded traffic for Chimagen Biosciences is 650 monthly website visits, up 51.2% over the last three months. Chimagen Biosciences's team grew 25% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Chimagen Biosciences in the Pudong ecosystem
The Chimagen Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
GSK
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Chimagen Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Chimagen Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










